Elutia Inc. (ELUT)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know
ELUTIA INC (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Elutia Inc. (ELUT) Q3 2025 Earnings Call Transcript
Elutia Inc. ( ELUT ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants C. Mills - Co-Founder, President, CEO & Director Matthew Ferguson - Chief Financial Officer Conference Call Participants Matt Steinberg Junwoo Park - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, everyone, and welcome to Elutia Third Quarter 2025 Financial Results Call.
All You Need to Know About ELUTIA INC (ELUT) Rating Upgrade to Buy
ELUTIA INC (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Elutia Inc. (ELUT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Elutia Inc. ever had a stock split?
Elutia Inc. Profile
| Biotechnology Industry | Healthcare Sector | C. Randal Mills CEO | NASDAQ (CM) Exchange | US05479K1060 ISIN |
| US Country | 51 Employees | - Last Dividend | - Last Split | 7 Sep 2023 IPO Date |
Overview
Elutia Inc. is a commercial-stage company operating in the United States with a focus on developing and commercializing drug-eluting biologics products. These innovative solutions are targeted towards neurostimulation, wound care, and breast reconstruction, amongst other applications. The company’s operations are structured into three distinct segments: Device Protection, Women's Health, and Cardiovascular, demonstrating its comprehensive approach to healthcare solutions. Originally known as Aziyo Biologics, Inc., the company underwent a name change to Elutia Inc. in September 2023, marking a new chapter in its development. Since its inception in 2015, Elutia Inc. has carved out a niche in the medical devices and biologics sector, operating out of its headquarters in Silver Spring, Maryland. The company’s products are designed to meet critical healthcare needs, serving hospitals and healthcare facilities through a combination of direct sales force, independent sales agents, and distributors.
Products and Services
- CanGaroo Envelope
An innovative solution designed to securely accommodate cardiac implantable electronic devices like pacemakers and internal defibrillators. This product underscores the company's dedication to improving post-surgical recovery and device integration.
- CanGarooRM
A step forward in surgical care, combining the CanGaroo envelope with antibiotics to significantly reduce the risk of infection following the implantation of electronic devices. This development showcases Elutia Inc.'s commitment to patient safety and care.
- ProxiCor
Designed for cardiac tissue repair and pericardial closure, ProxiCor represents a major advancement in cardiovascular surgery, providing surgeons with a biologically-compatible material for improved patient outcomes.
- Tyke
An extracellular material utilized in the delicate task of repairing cardiac structures in neonate and infant patients. Tyke exemplifies Elutia Inc.'s focus on addressing the specific needs of younger patients through specialized products.
- VasCure
A patch material used in the repair or reconstruction of the peripheral vasculature, showcasing the company's innovation in addressing vascular health and enhancing surgical success rates.
- SimpliDerm
Utilizing human acellular dermal matrices, SimpliDerm supports tissue repair and reconstruction across multiple applications. From sports medicine and hernia repair to trauma reconstruction and breast reconstruction surgeries following mastectomy, this product demonstrates Elutia Inc.'s versatility in biomedical solutions.
